Oragen Therapeutics
Oragen Therapeutics is developing an oral genetic medicine platform designed to deliver therapeutic nucleic acids directly to inflamed intestinal tissue, addressing the limitations of systemic biologics for inflammatory bowel disease. Its Nano-in-Micro Oral Delivery Platform uses a three-layer design to protect, target, and deliver payloads locally in the gastrointestinal tract. The lead program is a first-in-class oral siRNA candidate for IBD, currently in preclinical development.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Current treatments for inflammatory bowel disease (IBD), including biologics and small molecules, often require systemic administration, carry significant side effects, and lose effectiveness over time. Many patients fail to achieve durable remission or mucosal healing, leaving a substantial unmet need for therapies that act locally in the gut while minimizing systemic exposure and resistance.
Solution
Oragen Therapeutics is developing a novel oral RNA therapy platform designed to deliver therapeutic nucleic acids directly to inflamed intestinal tissue. The company's Nano-in-Micro Oral Delivery Platform protects the payload through oral administration and releases it locally in the gastrointestinal tract, enabling local production of therapeutic molecules at the disease site. This approach aims to achieve high efficacy with reduced systemic toxicity compared to injectable biologics. The lead program is a first-in-class oral siRNA candidate for IBD, currently in preclinical development. The platform is designed to be scalable to multiple inflammatory and gastrointestinal indications beyond IBD.
Target Audience
Primary users include gastroenterologists and IBD specialists treating patients with moderate-to-severe Crohn's disease or ulcerative colitis, as well as pharmaceutical partners seeking a differentiated oral genetic medicine delivery platform.
Features
- Nano-in-Micro Oral Delivery Platform with a three-layer design that protects, targets, and delivers nucleic acids through oral administration
- Proprietary formulation engineered for gastrointestinal stability and local release in intestinal tissue, including inflamed mucosa
- Designed to concentrate therapeutic activity at the disease site while limiting systemic exposure
- Lead program: first-in-class oral siRNA candidate for inflammatory bowel disease, in preclinical development
- Development path progressing toward IND-enabling studies
- Platform scalable to multiple gastrointestinal and inflammatory indications beyond IBD